Arteriosclerosis Thrombosis and Vascular Biology,
Год журнала:
2023,
Номер
44(1), С. 89 - 107
Опубликована: Ноя. 2, 2023
Both
cardiovascular
disease
(CVD)
and
cognitive
decline
are
common
features
of
aging.
One
in
5
deaths
is
cardiac
for
both
men
women
the
United
States,
an
estimated
50
million
currently
living
with
dementia
worldwide.
In
this
review,
we
summarize
sex
racial
differences
role
fish
its
very
long
chain
omega-3
polyunsaturated
fatty
acids,
eicosapentaenoic
acid
(EPA)
docosahexaenoic
(DHA),
preventing
CVD
events
decline.
prospective
studies,
higher
nonfried
intake
Black
individuals
plasma
levels
EPA
DHA
had
a
lower
risk
CVD.
randomized
controlled
trials
supplementation
primary
prevention,
subjects
benefited
secondary
outcome.
benefited,
Asians
as
prespecified
subgroup.
Fish
acids
associated
prevention
studies.
supplementation,
have
benefit.
seems
more
beneficial
than
EPA,
when
started
before
Although
studies
groups
limited,
life-long
lowers
decline,
also
show
benefit
supplementation.
These
findings
should
be
factored
into
recommendations
future
research
clinical
dietary
modalities
could
cost-effective
prevention.
Cardiovascular Research,
Год журнала:
2023,
Номер
119(18), С. 2884 - 2901
Опубликована: Дек. 1, 2023
Abstract
Omega-3
fatty
acids
(O3FAs)
possess
beneficial
properties
for
cardiovascular
(CV)
health
and
elevated
O3FA
levels
are
associated
with
lower
incident
risk
CV
disease
(CVD.)
Yet,
treatment
of
at-risk
patients
various
formulations
has
produced
disparate
results
in
large,
well-controlled
well-conducted
clinical
trials.
Prescription
fish
oil
supplements
containing
low-dose
mixtures
eicosapentaenoic
acid
(EPA)
docosahexaenoic
(DHA)
have
routinely
failed
to
prevent
events
primary
secondary
prevention
settings
when
added
contemporary
care,
as
shown
most
recently
the
STRENGTH
OMEMI
However,
observed
JELIS,
REDUCE-IT,
RESPECT-EPA,
EPA-only
significantly
reduce
CVD
high-risk
patients.
The
mechanism
action
EPA,
while
certainly
multifaceted,
does
not
depend
solely
on
reductions
circulating
lipids,
including
triglycerides
(TG)
LDL,
event
reduction
appears
related
achieved
EPA
suggesting
that
particular
chemical
biological
compared
DHA
other
O3FAs,
may
contribute
its
distinct
efficacy.
In
vitro
vivo
studies
different
effects
alone
or
EPA/DHA
combination
treatments,
atherosclerotic
plaque
morphology,
LDL
membrane
oxidation,
cholesterol
distribution,
lipid
dynamics,
glucose
homeostasis,
endothelial
function,
downstream
metabolite
function.
These
findings
indicate
prescription-grade,
provide
greater
benefit
than
O3FAs
tested.
This
review
summarizes
formulations,
their
efficacy
treating
disease,
underlying
mechanisms
action.
Journal of Cardiovascular Development and Disease,
Год журнала:
2025,
Номер
12(2), С. 60 - 60
Опубликована: Фев. 5, 2025
Vascular
endothelial
function
plays
an
important
role
in
the
pathogenesis
of
atherosclerosis.
The
reduction
low-density
lipoprotein
cholesterol
(LDL-C)
is
a
key
therapy
for
preventing
coronary
artery
disease
(CAD),
but
omega-3
fatty
acids
as
residual
risk
factors
CAD
remains
controversial.
We
studied
correlation
between
serum
acid
levels
and
patients
with
receiving
statin
examined
effect
eicosapentaenoic
(EPA)
on
function.
A
total
150
consecutive
(LDL-C
<
100
mg/dL)
were
enrolled.
Serum
measured,
was
assessed
by
flow-mediated
dilation
(FMD)
brachial
artery.
Subsequently,
65
impaired
FMD
(<6%)
low
EPA/arachidonic
(AA)
(<0.3)
administered
EPA,
reassessed
after
3
months.
multivariate
linear
regression
analysis
demonstrated
that
docosahexaenoic
(DHA)
EPA
plus
DHA
independent
determinants
%FMD
(β
=
0.214
0.163,
p
0.05,
respectively).
significantly
improved
(from
3.7
±
1.0%
to
4.1
1.0%,
0.05)
EPA/AA,
especially
EPA/AA
high
triglyceride
3.4
4.0
1.1%,
0.01).
associated
dysfunction
therapy.
improves
those
triglycerides.
Journal of the American Heart Association,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 19, 2025
The
efficacy
of
icosapent
ethyl
among
patients
with
very
well-controlled
baseline
low-density
lipoprotein
cholesterol
(LDL-C)
is
unknown.
In
this
post
hoc
analysis
the
REDUCE-IT
(Reduction
Cardiovascular
Events
With
Icosapent
Ethyl-Intervention
Trial)
randomized
clinical
trial,
statin-treated
high
cardiovascular
risk,
elevated
triglycerides
(135-499
mg/dL),
and
LDL-C
41
to
100
mg/dL
were
included.
Patients
(2
g
twice
daily)
or
placebo
then
stratified
by
(<55
versus
≥55
mg/dL).
primary
composite
end
point
included
death,
nonfatal
myocardial
infarction,
stroke,
coronary
revascularization,
unstable
angina.
Among
8175
data,
7117
(87.1%)
had
1058
(12.9%)
<55
mg/dL.
mg/dL,
rate
was
lower
in
group
(16.2%
22.8%)
than
(hazard
ratio
[HR],
0.66
[95%
CI,
0.50-0.87];
absolute
risk
reduction,
6.6%;
P=0.003).
a
event
occurred
proportion
(17.4%
21.9%)
(HR,
0.76
0.69-0.85];
4.5%;
P<0.0001).
No
significant
interaction
observed
between
treatment
(P
for
interaction=0.40).
Findings
consistent
secondary
points
sensitivity
analyses.
reduced
irrespective
LDL-C,
including
eligible
optimal
control.
URL:
https://www.clinicaltrials.gov;
Unique
identifier:
NCT01492361.
Frontiers in Cardiovascular Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Авг. 7, 2024
Historically,
atherosclerotic
cardiovascular
disease
(ASCVD)
risk
profile
mitigation
has
had
a
predominant
focus
on
low
density
lipoprotein
cholesterol
(LDL-C).
In
this
narrative
review
we
explore
the
residual
ASCVD
beyond
LDL-C
with
hypertriglyceridaemia,
recent
clinical
trials
of
therapeutics
targeting
hypertriglyceridaemia
and
novel
modalities
addressing
other
factors.
Journal of the American Heart Association,
Год журнала:
2024,
Номер
13(14)
Опубликована: Июль 3, 2024
Endothelial
cell
(EC)
dysfunction
involves
reduced
nitric
oxide
(NO)
bioavailability
due
to
NO
synthase
uncoupling
linked
increased
oxidation
and
cofactor
availability.
Loss
of
endothelial
function
are
associated
with
inflammation,
including
leukocyte
activation.
Eicosapentaenoic
acid
(EPA)
administered
as
icosapent
ethyl
cardiovascular
events
in
REDUCE-IT
(Reduction
Cardiovascular
Events
With
Icosapent
Ethyl-Intervention
Trial)
relation
on-treatment
EPA
blood
levels.
The
mechanisms
protection
for
remain
incompletely
elucidated
but
likely
involve
direct
effects
on
the
endothelium.
Expert Opinion on Pharmacotherapy,
Год журнала:
2025,
Номер
unknown, С. 1 - 11
Опубликована: Янв. 11, 2025
Introduction
Atherogenic
dyslipidemia
with
increased
triglycerides,
low
high-density
lipoprotein
cholesterol
levels
and
small
dense
low-density
(LDL)
particles
is
a
major
risk
factor
contributing
to
the
cardiovascular
(CV)
in
patients
type
2
diabetes
(T2D).
This
regarded
as
residual
after
achieving
target
of
LDL
cholesterol.
Stroke Vascular and Interventional Neurology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 4, 2025
BACKGROUND
Patent
foramen
ovale
(PFO)
contributes
to
a
quarter
of
embolic
strokes
undetermined
source.
Although
the
benefit
PFO
closure
in
selected
patients
has
been
demonstrated,
our
system
workflow
still
resulted
low
rate
evaluation
for
closure.
The
aim
PFO‐ACCESS
(Augmenting
Communications
Medical
Care
or
Closure
Evaluation
Stroke
Patients
With
Cardiac
Shunts)
program
(which
included
implementation
Viz.ai
PFO‐specific
communications
module)
was
determine
if
there
any
change
management
due
improved
communication
between
stroke
and
interventional
cardiology
teams.
METHODS
In
this
quality
improvement
project,
we
compared
pre‐PFO
ACCESS
(December
2022–November
2023)
post‐PFO
periods
(November
2023–June
2024)
regarding
evaluations.
module
implemented
teams
without
other
changes.
Key
performance
indicators
referral
frequency,
rates,
time
intervals.
Statistical
comparisons
utilized
Mann–Whitney
U
,
chi‐square,
Fisher's
exact,
exact
Poisson
test
where
appropriate.
RESULTS
postimplementation
period
noted
492%
increase
(11
versus
38,65
[annualized];
P
<0.0001).
number
totals
showed
186%
nonsignificant
pre
post
(6
10,17
=
0.99),
with
percentage
total
referred
cases
showing
large
but
decrease
(54.55%,
26.32%;
0.14).
Time
marked
median
“referral
sent
viewed”
(10:37
hours,
1:08
hours;
0.73),
accepted”
1:03
0.67)
interval,
closure”
interval
(102
days,
97
days;
0.55).
CONCLUSION
use
referrals
enhanced
efficiency
managing
PFO‐related
cases.
Though
increased
closures
were
observed,
indicating
selective
case
management.
higher
shows
that
more
are
indeed
appropriate
consideration.
Future
efforts
should
focus
on
expanding
outpatient
increasing
provider
education
optimize
